echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Sanofi and verily set up onduo, a diabetes joint venture

    Sanofi and verily set up onduo, a diabetes joint venture

    • Last Update: 2016-09-13
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Source: Sina Pharmaceutical News 2016-09-13 on Monday, Sanofi and verily (formerly Google Life Sciences) announced that they had jointly invested in the creation of ondoo, a diabetes focused company The previous year, Sanofi worked with Google life sciences to monitor diabetes Stefan oerlich, Sanofi's global diabetes specialist, told fierce medical devices that the two companies will each invest $248 million in onduo Ondoo said in a statement that it aims to develop a solution that combines devices, software, drugs and professional care to help diabetics better manage their own diseases The joint venture is trying to integrate these tools more into a 'service-oriented' approach rather than simply using a single tool In a statement, Peter guter, executive vice president of Sanofi and head of the global diabetes and Cardiovascular Division, said ondoo will adopt a more "service-oriented" approach to help doctors treat patients more effectively "In addition to maintaining Sanofi's key work (developing innovative therapies to treat diabetes), we hope to integrate these innovative therapies and services with diabetes clinical care in the future." But the statement did not elaborate, including "the potential to integrate multiple interventions" (such as data-based patient support and devices to change outcomes) Oerlich declined to provide details, saying the work was still 'in progress' For a long time, Sanofi's diabetes business has not been smooth Last month, the FDA asked the company for detailed data on its dual insulin syringes Sanofi's competitor Novo Nordisk's syringes contain basic insulin and GLP-1 drugs, which are expected to receive FDA approval this month, which is likely to frustrate Sanofi's market share in this area In October last year, Sanofi said its diabetes business had seen a decline in revenue and expected continued declines Sanofi has been trying to overcome the challenges of new drugs and European biosimilars, but the effect is not good Afrezza, the company's inhaled insulin drug, has been abandoned because of its poor performance since its release Later it released toujeo drugs, but due to the fierce competition and the advantage of generic drugs such as Lantus, toujeo's market share is not optimistic  
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.